EsophyX™ (Endoluminal Fundoplication™) ELF System for GERD

EsophyX™ is a minimally invasive device for the treatment of gastroesophageal reflux disease. Already approved in the EU, the device is designed to perform endoluminal fundoplication procedures (ELF) for the creation of gastroesophageal valves and reduction of hiatal hernias. In a new press release, EndoGastric Solutions, Inc., a Redmond, Washington company, is reporting that in a European study of 84 patients “92% of patients were no longer taking daily Proton Pump Inhibitors (PPIs) and 10% were taking only occasional PPIs with an average dosage of less than 30mg per week” after three months of follow up after the surgery. According to the company, the study was designed to further evaluate the device and to help obtain the U.S. FDA clearance for EsophyX™.
To understand how the device works, head on to the product page and check out the flash video presentation…
Press release: EndoGastric Solutions Announces 92% success in eliminating daily drug dependence in their European EsophyX ELF pivotal trial of an incisionless surgical treatment for GastroEsophageal Reflux Disease (GERD) …